Drugs / LANCOVUTIDE
LANCOVUTIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00671736 | Oct 2007 → Jul 2009 | cystic fibrosis | AOP Orphan Pharmaceuticals AG | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LANCOVUTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108327 ↗ |
| Known as | Duramycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108327 ↗ |
| Known as | Lancovutida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108327 ↗ |
| Known as | Leucopeptin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108327 ↗ |
| Known as | Moli1901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00671736 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2108327 ↗ |